---
title: "Petrelintide"
canonical_url: https://peptidelibrary.app/library/petrelintide
description: "Investigational long-acting amylin receptor agonist from Zealand Pharma, engineered for once-weekly dosing and in clinical development for obesity. Amylin agonists reduce food intake through hindbrain pathways separate from incretin signalling, so they are being studied both alone and alongside GLP-1 receptor agonists. Not FDA-approved."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Petrelintide

Petrelintide (also called ZP8396 or Long-acting amylin analog) is an investigational amylin analog. Petrelintide is a long-acting amylin receptor agonist in clinical development, engineered for stability and once-weekly administration. It engages amylin and calcitonin receptor complexes in hindbrain nuclei, principally the area postrema, where amylin signalling slows gastric emptying and reduces meal size.

Investigational long-acting amylin receptor agonist from Zealand Pharma, engineered for once-weekly dosing and in clinical development for obesity. Amylin agonists reduce food intake through hindbrain pathways separate from incretin signalling, so they are being studied both alone and alongside GLP-1 receptor agonists. Not FDA-approved.

Also known as: ZP8396, Long-acting amylin analog.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: Investigational amylin analog
- Mechanism class: Amylin Agonist
- Development stage: In clinical development
- Regulatory class: Investigational, not FDA-approved

## Mechanism

Petrelintide is a long-acting amylin receptor agonist in clinical development, engineered for stability and once-weekly administration. It engages amylin and calcitonin receptor complexes in hindbrain nuclei, principally the area postrema, where amylin signalling slows gastric emptying and reduces meal size. The developmental thesis for amylin agonists is that they reduce food intake through a mechanism distinct from incretin signalling, potentially with a different tolerability profile, and can be used alone or alongside a GLP-1 receptor agonist. Efficacy and safety remain under investigation and it is not approved for any use.

Targets: Amylin receptor.

Origin: Synthetic long-acting amylin analog.

## Properties

- Molecular formula: —
- Half-life: About 10 days (phase 1 trials)
- Studied routes: Subcutaneous

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 3
- Controlled human trials: 3
- Preclinical sources: 0
- Latest source: 2026

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2026. 2026. Controlled human trial. Population: Adults with obesity, or BMI ≥27 with hypertension or dyslipidaemia, without type 2 diabetes (485 dosed). Mean weight change from -7.9% to -9.8% across doses against -1.7% with placebo; nausea in 20% against 6% [Source](https://pubmed.ncbi.nlm.nih.gov/42810355/)
2. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes Obes Metab. 2026. 2026. Controlled human trial. Population: Adults of normal weight or overweight (single dose and MAD part 1); adults with overweight or obesity (MAD part 2). Well tolerated with no serious or severe adverse events; weight down by up to 8.6% after 16 weeks [Source](https://pubmed.ncbi.nlm.nih.gov/42017294/)
3. NCT07843472 — A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease. Controlled human trial. Population: Adults with overweight or obesity and established cardiovascular disease (n=2,500 planned). Recruiting; no results [Source](https://clinicaltrials.gov/study/NCT07843472)

### Registered trials

- [NCT07843472](https://clinicaltrials.gov/study/NCT07843472)

## Safety

Side effects: Nausea; GI effects.

Risks: Not approved; WADA S0.

Human safety basis: Clinical trial reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

Petrelintide has been studied under an Investigational New Drug application. It is not approved for marketing.

- FDA status: Investigational New Drug (IND)
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### How does Petrelintide work?

Petrelintide is a long-acting amylin receptor agonist in clinical development, engineered for stability and once-weekly administration. It engages amylin and calcitonin receptor complexes in hindbrain nuclei, principally the area postrema, where amylin signalling slows gastric emptying and reduces meal size.

### Is Petrelintide FDA approved?

No. Petrelintide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.

### What is the half-life of Petrelintide?

Reported half-life for Petrelintide is Long-acting (once-weekly; precise human t½ not yet widely published). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Petrelintide banned in sport?

Petrelintide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to Petrelintide?

Compounds most often compared with Petrelintide include Cagrilintide, Pramlintide, CagriSema and Amycretin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials — Diabetes Obes Metab, 2026](https://pubmed.ncbi.nlm.nih.gov/42017294/)
- [Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue — J Med Chem, 2025](https://pubmed.ncbi.nlm.nih.gov/41217931/)
- [Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies — Vascul Pharmacol, 2026](https://pubmed.ncbi.nlm.nih.gov/41344603/)
- [Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes — Peptides, 2026](https://pubmed.ncbi.nlm.nih.gov/41747885/)
- [Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs — Pharmacol Res, 2026](https://pubmed.ncbi.nlm.nih.gov/42586227/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
